Navigate to Other Sector


Healthcare Newsletter – February 2019

Complex generics - High price erosion benchmarks from Mylan’s Advair launch significant cause of concern for inhalation products
Medical Devices: Mainstream interest in robotics drives M&A – J&J acquires Auris
Big ticket M & A – continued thrust on rare diseases and next gen therapies (microbiome & gene therapy)
Diabetes Care becoming more comprehensive– drug-device collaborations paving the way
Biosimilars: US Adalimumab opportunity continues to be a mirage while Bevacizumab seems closer to market with Pfizer’s EU approval

Discussion — No responses

Show Buttons
Hide Buttons